Document is current

Article History

Received: 10 October 2025

Accepted: 20 October 2025

First Online: 11 December 2025

Declarations

:

: The ART-transition study will be conducted in accordance with the Declaration of Helsinki and the principles outlined in Good Clinical Practice, adhering to the guidelines outlined in the NHS Research Governance Framework for Health and Social Care (2nd edition). Ethical Approval was obtained from the Nottingham 1 Research Ethics Committee (24/EM/0227). All staff working on the study have received training in study conduct, informed consent and risk assessment. RMT data will be pseudonymised and stored in a research database in accordance with the General Data Protection Regulation. The informed consent process will ensure that participants understand the nature of the study and the data being collected. Interested individuals will be sent the study materials, including an information sheet and a consent form to review. If, after reading, they wish to participate, they will be invited to an enrolment session, which will involve the collection of written consent before the administration of any study procedures. They will understand that their privacy is protected and that they can withdraw at any time without giving a reason. While it is not a requirement for participants to be in contact with healthcare services during the study, for those who are, their relationships with their care teams will not be impacted by participation or withdrawal from the study.

: Not applicable.

: Prof. Jonna Kuntsi has given talks at educational events sponsored by Medice; all funds are received by King’s College London and used for studies of ADHD. Amos A. Folarin reports holding shares in Google, the parent company of Fitbit, which produces the wearable devices utilised in the ART-transition study to collect data. Neither Google nor Fitbit provided funding or devices for this study. All other authors declare no competing interests.